ReNAgade Therapeutics Management, Inc. logo

ReNAgade Therapeutics Management, Inc.

7 Marks
Corp.
First Filed:Oct 5, 2022Latest Filed:Oct 18, 2023Address:500 Forge Rd., Watertown, MA 02472

Portfolio Overview

Pending
2(29%)
Dead
5(71%)

Top Classes

Class 5
Pharmaceuticals
7(100%)
Class 1
Industrial Chemicals & Adhesives
7(100%)
Class 42
Software, IT Services & Scientific Research
7(100%)

TTAB Proceedings

No litigation activity

Top Firms

Pierce Atwood LLP(Oct 2023)
7

Trademark Portfolio

7 results

(current & previous marks)

Refine by Mark/Description🔽
Filed
Registered
Last Activity
RNGD
RNGD
Trademark
Word
ABANDONED
Owner:
Serial:98229306
Filed:Oct 18, 2023
Classes:1, 5, 42
Goods & Services
Pharmaceutical and biological preparations and substances, namely, preparations for the treatment of hemoglobinopathies, cancer, infectious diseases, autoimmune diseases and disorders, immune-mediated diseases and disorders, and inflammatory diseases and disorders; Pharmaceutical preparations, namely, nucleic acid therapeutics and delivery vehicles being RNA and DNA therapeutics for scientific, research, medical, or pharmaceutical use; Pharmaceutical preparations, namely, nucleic acid therapeutics and delivery vehicles being RNA and DNA therapeutics which constitute and encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for scientific, research, medical, or pharmaceutical use; Human and veterinarian vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, reproductive disorders, infectious diseases for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations in the nature nucleic acid delivery agents; Chemical and biological reagents for medical or veterinary purposes, namely, for nucleic acid therapy; Biological preparations for medical, pharmaceutical or veterinary purposes, namely, for use in connection with nucleic acid therapy; Pharmaceutical and veterinary preparations, namely, nano particles to improve delivery of plasmid DNA and messenger RNA molecules; nano particles for the delivery of pharmaceutical or veterinary agents and preparations; nano particles for drug delivery; engineered nucleic acids for delivery of therapeutic DNA or mRNA sequences to cells, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Enzymes and nucleic acid sequences for medical use, namely, for the modification of cells and RNA and DNA; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and RNA and DNA editing; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene, genome, and cellular editing, modulation, and modification for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; Enzymes, nucleic acid molecules, and compounds/agents for modifying small RNAs with targeting agents for medical use, namely, use of the modified small RNAs in the gene editing industry; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations for gene therapy and mRNA regulation; Drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds directed to lipid nanoparticles for the purpose of delivering pharmaceutical preparations to specific target tissue sites; drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds and agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations; drug delivery agents consisting of pharmaceutical preparations and therapeutic agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations for RNA, gene therapy and mRNA regulation; drug delivery agents consisting of pharmaceutical and biological preparations for medical use that facilitate the release and delivery of a wide variety of pharmaceutical preparations for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; drug delivery agents consisting of pharmaceutical preparations that facilitate the release and delivery of a wide variety of pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; Pharmaceutical preparations, lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and small molecule compounds for medical use; Biochemical preparations for scientific purposes; Biochemicals for use in the manufacture of RNA therapeutics and DNA therapeutics; Biochemicals for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Diagnostic preparations for scientific, research, clinical and medical laboratory use; chemicals for use in pharmaceutical, biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Nucleic acid for laboratory use; Protein in raw material form for scientific and medical research; Reagents for scientific and research use and for testing the sterility of pharmaceuticals; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Antioxidants for use in the manufacture of pharmaceuticals; Biochemicals for in vitro, in vivo, or ex vivo scientific use; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Cells for scientific, laboratory or medical research; Chemical additives for use in the manufacture of pharmaceuticals; Chemicals for use in the biochemical and chemical industry; Enzymes for use in protein hydrolysis; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Plant extracts for use in the manufacture of pharmaceuticals; Protein arrays and nucleotide arrays for scientific and medical research; chemical reagents for scientific or research use, namely, used in gene or nucleic acid delivery systems; nano-particles, namely, those composed predominantly of polymers, used in the manufacture of pharmaceuticals; genome editing reagents for research purposes; genome engineering reagents for scientific and research purposes; genome editing and amplification reagents for scientific and research purposes; Chemical and biological agents for scientific and research use, namely, for manipulating or modifying RNA and DNA; enzymes for scientific and research purposes; enzyme preparations for use in the gene editing industry; Nucleic acid sequences for other than medical and veterinary purposes; Chemical and biological agents for scientific and research use, namely, for the modification of small RNAs with targeting agents and for regulating expression and/or levels of mRNA with the modified RNAs; enzyme preparations for use in modifying small RNAs and for use of modified small RNAs in the gene editing industry; Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acids and modified nucleic acids, namely, short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes; Pharmaceutical research and development; Scientific research and development; Vaccine research and development; Research and development in the pharmaceutical and biotechnology fields and in the fields of vaccines, medicines and antibodies; Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering and scientific research in the fields of genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, in the field of pharmaceutical and biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles; Testing of pharmaceuticals and biotherapies; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Medical and scientific research in the field of cancer treatment and diagnosis; Scientific research for medical purposes in the field of nucleic acids, inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Research in the fields of pharmaceutical and biological therapeutic preparations, namely, nucleic acid delivery systems; conducting clinical trials for others in the field of hemoglobinopathies, cancer, infectious diseases, autoimmune diseases and disorders, immune-mediated diseases and disorders, and inflammatory diseases and disorders; Research and development in the field of technology and engineering for the modification of RNA and DNA and gene editing technology; development of new technology for others for enabling the engineering and modification of RNA and DNA, namely, developing molecular and cellular biology reagents, techniques, and assays for the modification of cells and RNA and DNA; Research and development in the field of technology and engineering RNAs with targeting agents for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of RNA with targeting agents, namely, developing molecular and cellular biology reagents, techniques, and assays for use in the gene editing industry; Research and development in the field of technology and engineering, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, drug delivery agents and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, drug delivery agents and assays for use in pharmaceutical and biomedical industry
CELEST
CELEST
Trademark
Word
ITU
PENDING
Owner:
Serial:98219801
Filed:Oct 11, 2023
Classes:1, 5, 42
Goods & Services
Drug delivery agents in the form of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds directed to lipid nanoparticles for the purpose of delivering pharmaceutical preparations to specific target tissue sites; drug delivery agents in the form of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds and agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations; drug delivery agents consisting of pharmaceutical preparations and therapeutic agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations for RNA, gene therapy and mRNA regulation; drug delivery agents consisting of pharmaceutical and biological preparations for medical use that facilitate the release and delivery of a wide variety of pharmaceutical preparations for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; drug delivery agents consisting of pharmaceutical preparations that facilitate the release and delivery of a wide variety of pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; pharmaceutical preparations, namely, vaccines; Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acids and modified nucleic acids, namey, short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes; Research and development in the field of technology and engineering, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, drug delivery agents and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, drug delivery agents and assays for use in pharmaceutical and biomedical industry
PRL
PRL
Trademark
Word
ABANDONED
Owner:
Serial:98214461
Filed:Oct 9, 2023
Classes:1, 5, 42
Goods & Services
Lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and small molecule compounds for medical use; pharmaceutical preparations and therapeutic agents, namely, for RNA, gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid formulations, nucleic acids and modified nucleic acids, namely, short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes; Research and development in the field of technology and engineering of lipids, lipid nanoparticles, lipid formulations and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, and assays for use in pharmaceutical and biomedical industry
CRST
CRST
Trademark
Word
ABANDONED
Owner:
Serial:98201920
Filed:Sep 28, 2023
Classes:1, 5, 42
Goods & Services
Enzymes, nucleic acid molecules, and compounds and agents for modifying small RNAs with targeting agents for medical use, namely, use of the modified small RNAs in the gene editing industry; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; Chemical and biological agents for scientific and research use, namely, for the modification of small RNAs with targeting agents and for regulating expression and levels of mRNA with the modified RNAs; enzymes for scientific and research purposes; enzyme preparations for use in modifying small RNAs and for use of modified small RNAs in the gene editing industry; Nucleic acid sequences for other than medical and veterinary purposes; Research and development in the field of technology and engineering RNAs with targeting agents for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of RNA with targeting agents, namely, developing molecular and cellular biology reagents, techniques, and assays for use in the gene editing industry
NICKL
NICKL
Trademark
Word
ABANDONED
Owner:
Serial:98152850
Filed:Aug 28, 2023
Classes:1, 5, 42
Goods & Services
Enzymes and nucleic acid sequences for medical use, namely, for the modification of cells and RNA and DNA; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and RNA and DNA editing; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene, genome, and cellular editing, modulation, and modification for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene editing; Chemical and biological agents for scientific and research use, namely, for manipulating or modifying RNA and DNA; enzymes for scientific and research purposes; enzyme preparations for use in the gene editing industry; Nucleic acid sequences for other than medical and veterinary purposes; Research and development in the field of technology and engineering for the modification of RNA and DNA and gene editing technology; development of new technology for others for enabling the engineering and modification of RNA and DNA, namely, developing molecular and cellular biology reagents, techniques, and assays for the modification of cells and RNA and DNA
RENAGADE THERAPEUTICS
RENAGADE THERAPEUTICS
Trademark
Word
ITU
PENDING
Owner:
Serial:97620656
Filed:Oct 5, 2022
Classes:1, 5, 42
Goods & Services
Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy containing polypeptide encoding nucleic acids for the prevention and/or treatment of rare diseases, cancers, diabetes, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for in vitro, in vivo, or ex vivo delivery to a cell, organ, tissue, or body; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of infectious diseases, blood disorders, diabetes, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for the prevention of osteoporosis; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics for the treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral infections; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for treating diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for use in chemotherapy; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, namely, antivirals; Vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; veterinarian vaccine preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral and joint diseases; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, and chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, and for use in the manufacture of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Reagents for testing sterility of pharmaceuticals; Diagnostic reagents for scientific or research use; chemicals for use in biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use; Biochemical catalysts; Biochemical preparations for scientific purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations used in science; Nucleic acid for laboratory use; Protein in raw material form for scientific and medical research; Reagents for research purposes; Reagents for scientific and research use; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Antioxidants for use in the manufacture of pharmaceuticals; Biochemicals for in vitro, in vivo, and ex vivo scientific use; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Cells for scientific, laboratory or medical research; Chemical additives for use in the manufacture of pharmaceuticals; Chemicals for use in the biochemical and chemical industry; Chemicals for use in the purification of proteins for in vitro use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Enzymes for use in protein hydrolysis; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Plant extracts for use in the manufacture of pharmaceuticals; Protein arrays and nucleotide arrays for scientific and medical research; Reagents for scientific or medical research use; "THERAPEUTICS"; Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering, genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy and cell therapy, research, development and testing services in the field of pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics in the nature of linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Medical and scientific research in the field of cancer treatment and diagnosis; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of nucleic acids, inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Pharmaceutical research and development; Product research and development; Scientific research and development; Vaccine research and development
RENEGADE THERAPEUTICS
ABANDONED
Owner:
Serial:97620671
Filed:Oct 5, 2022
Classes:1, 5, 42
Goods & Services
"THERAPEUTICS"

Cookie Preferences

We use cookies (including Google Analytics) to improve our site and understand how visitors use it.